Navigation Links
Pipeline for Lung Cancer Therapies is Focus of New MedPredict Report
Date:2/19/2008

SCOTTSDALE, Ariz., Feb. 19 /PRNewswire/ -- MedPredict has published a new report in its oncology series entitled "Thought Leader Insight & Analysis: Lung Cancer," designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for diagnostics and treatments in non-small cell and small cell lung cancer.

Lung cancer continues to be the leading worldwide cause of cancer death. Researchers are pursuing a broad array of mechanistic approaches to treatment, including angiogenics/VEGF, EGFR resistance (T790M, MET), HER2 (ErbB2), antifolate, anti-microtubule, apoptosis, Bcl-2/Bcl-xL, TRAIL, vascular disrupting agents, Ras, Raf, MEK, mTOR, PI3, AKT, IGF-1, HSP90, HDAC, JAK/STAT, MAGE-A3, CDK, Aurora Kinase, and anticoagulation.

MedPredict conducted primary, qualitative interviews with renowned US-based Thought Leaders in the areas of non-small cell and small cell lung cancer in order to identify the most promising candidates in clinical development, as well as explore unmet needs. "This report will provide essential strategic insight for those involved in development of lung cancer therapies," according to MedPredict President Dr. Jeffrey Berk. "Our Thought Leader Panel discusses ongoing clinical programs, and offers their opinions on which of the myriad new drugs in development are likely to be significant improvements over current options."

Some of the companies/partnerships discussed in this report include: Genentech/Roche, Pfizer, AstraZeneca, GlaxoSmithKline, Onyx/Bayer-Schering, Regeneron/Sanofi-Aventis, Genentech/OSI, Imclone/BMS/Merck Serono, Lilly, Exelixis, Wyeth, Boehringer-Ingelheim, Novartis, Mitsubishi/Aveo, Cell Therapeutics, Abbott/Genentech, Genentech/Amgen, Antisoma/Novartis, Antigenics, Concordia, Prolexys, Critical Outcome Technologies, Merck, Schering-Plough, Infinity/Medimmune/AstraZeneca, Synta, Serenex, Bristol Myers Squibb, Abbott, Millennium, Vertex/Merck, Cyclacel.

The full report can be purchased by contacting MedPredict.

About MedPredict

MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
2. Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations
3. Progen Expands Drug Development Pipeline Through Acquisition of CellGate
4. Monsantos R&D Pipeline Set to Deliver Valuable Products to Farmers Well Into Next Decade
5. Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline
6. Lighting the Onco-Pipeline, Stem Cell Cancer, and More at Global Cancer Congress, January 28-29, 2008, Tampa
7. Michigan Life Sciences Pipeline to Kick Off MichBio Expo
8. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
9. More than $6 Million Raised During Two-Day Event to Support Research and Treatment for Childhood Cancer and Other Catastrophic Diseases
10. Accelerated Community Oncology Research Network, Inc. (ACORN), Initiates a Phase 2b Metastatic Breast Cancer Trial in Cooperation With Bayer and Onyx
11. New Technology for Early Detection of Lung Cancer Selected for Clinical Study With Veterans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... MONICA, Calif. , June 23, 2016  The Prostate Cancer Foundation ... pioneer increasingly precise treatments and faster cures for prostate cancer. Members of the ... institutions across 15 countries. Read More About the Class ... ... ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ON (PRWEB) , ... June 23, 2016 , ... STACS ... DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as ... the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
Breaking Biology Technology:
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:6/1/2016)... , June 1, 2016 Favorable ... Election Administration and Criminal Identification to Boost Global Biometrics ... recently released TechSci Research report, " Global Biometrics Market ... Competition Forecast and Opportunities, 2011 - 2021", the global ... by 2021, on account of growing security concerns across ...
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
Breaking Biology News(10 mins):